SemBioSys, insulin data

Oct. 26, 2007 - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, announced that it will be presenting a scientific poster and abstract at the Seventh Annual Diabetes Technology Meeting in San Francisco hosted by the Diabetes Technology Society. The poster will disclose SemBioSys' recent accomplishments in the development of a highly-scalable, low-cost source of recombinant human insulin... SemBioSys' Press Release -

Synvista's Alagebrium, Potential for use in Treating Diabetes-Related Gastrointestinal Complications

Oct. 25 , 2007 - Synvista Therapeutics, Inc. (AMEX: SYI) announced the publication of preclinical data demonstrating the ability of its compound, alagebrium, to reduce serum levels of advanced glycated end-products (AGEs) and restore neuronal nitric oxide synthase (nNOS) activity in rats with diabetes... Synvista's Press Release -

Isis, New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes

Oct 18, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that acts in the kidney to increase glucose excretion, complements Isis' existing pipeline of drugs in development for the treatment of diabetes, each of which act upon targets in the liver through distinct mechanisms to improve insulin sensitivity, reduce glucose production*, or affect other metabolic aspects of this complex disease... Isis' Press Release -

Lilly and MacroGenics, Licensing and Collaboration Agreement

10/18/2007 – Eli Lilly and Company (NYSE:LLY) and MacroGenics, Inc. announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases. As part of the deal, Lilly will acquire the exclusive rights to the molecule. Teplizumab is currently being studied in the PROTÉGÉ trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes*... MacroGenics' Press Release - Lilly's Press Release -

Flamel Technologies, Positive Results of a Phase I Trial

October 18, 2007 - Flamel Technologies (NASDAQ:FLML) announced positive preliminary Phase I data from a trial comparing the safety, tolerability, and long-acting activity of FT-105 versus Lantus , an approved basal insulin. FT-105 is a long-acting recombinant insulin formulation that uses a new microparticulate adaptation of Flamel's proprietary Medusa® nanoparticle delivery system... Flamel Technologies' Press Release -

Generex Biotechnology, Contract Research Organization to Manage Global Phase III Trials For Generex Oral-lyn

Oct. 16, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it has entered into a number of key service agreements for its global Phase III trials for Generex Oral-lyn, its proprietary oral insulin spray product... Generex Biotechnology's Press Release -

DARA BioSciences and Bayer Pharmaceuticals, Exclusive License Agreement

October 17, 2007 - DARA BioSciences, Inc. and Bayer Pharmaceuticals Corporation (BPC), a U.S. subsidiary of Bayer HealthCare AG signed a license agreement granting DARA BioSciences exclusive worldwide rights to a series of patents and compounds for the treatment of metabolic diseases, in particular type 2 diabetes and dyslipidemia. Lead compounds are in later preclinical development... DARA BioSciences' Press Release -

Merck , Supplemental New Drug Applications for JANUVIA

Oct. 17, 2007 - Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA™ (sitagliptin), the only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin.... Merck's Press Release -

Johnson & Johnson, Global Diabetes Institute

October 16, 2007– Johnson & Johnson (NYSE: JNJ) announced the establishment of the Johnson & Johnson Diabetes Institute (JJDI) to transform diabetes care by providing comprehensive training on the latest practice standards, new diabetes tools and technologies and reimbursement solutions to physicians, nurses, physician assistants and diabetes educators around the globe... Johnson & Johnson's Press Release -

Exelixis, Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy

Oct. 16, 2007 - Exelixis, Inc. (Nasdaq: EXEL) announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy... Exelixis' Press Release -

Hollis-Eden Pharmaceuticals, Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Obese, Insulin Resistant Volunteers

Oct. 16, 2007--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that it is commencing this week a two-stage Phase I/II clinical trial with its oral drug candidate TRIOLEX(TM) (HE3286) in obese, insulin resistant volunteers. TRIOLEX represents a novel class of insulin sensitizers that the Company believes acts by modulating the anti-inflammatory pathway NF-kappaB... Hollis-Eden Pharmaceuticals' Press Release -

Living Cell Technologies, Positive Preliminary Data From DiabeCell® Phase I/IIa Trial in Type I Diabetes

October 9, 2007 - Living Cell Technologies Limited (ASX: LCT) released positive preliminary results for its Phase I/IIa clinical trial of the company's proprietary DiabeCell® porcine for the treatment of type 1 diabetes. The clinical trial is being conducted in six type 1 (insulin-dependent) diabetic patients... Living Cell Technologies' Press Release -

Isis, $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007

Calif., Oct 09, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has received a $1.25 million milestone payment in the form of equity securities in iCo Therapeutics. The milestone was related to the initiation of Phase 1 clinical trials of iCo-007, a drug licensed to iCo by Isis in 2005 for the treatment of various eye diseases, including diabetic macular edema...
Isis' Press Release - iCo's Press Release -

Johnson & Johnson Pharmaceutical R & D, Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

October 8, 2007 – Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including some infections that were caused by methicillin-resistant Staphylococcus aureus (MRSA)... Johnson & Johnson's Press Release -

Akesis Pharmaceuticals , IND for Phase IIa Trial of AKP-020 to Treat Type 2 Diabetes

Oct 8, 2007 - - Akesis Pharmaceuticals, Inc. (OTC/BB: AKES), an emerging diabetes drug-development company, announced that it has filed its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead product candidate AKP-020, a novel vanadium compound that is expected to show considerable potential as a treatment for patients with Type 2 Diabetes... Akesis' Press Release -

Alimera Sciences and pSivida , Pivotal Phase 3 Trial of Medidur™ FA for Diabetic Macular Edema

October 08, 2007 - Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI), announced that enrollment is complete for the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur™ FA for the treatment of Diabetic Macular Edema...
Alimera Sciences' Press Release - pSivida's Press release -

MyCareTeam, New Diabetes Tool Available on ADA Web Site

October 4, 2007– The American Diabetes Association unveiled a new web-based diabetes tool that makes it easier for people with diabetes – and their care providers – to share and organize important health information to improve their diabetes care. The tool, My Diabetes Connector, is a diabetes management software application developed by
a software and services company, MyCareTeam, Inc...
ADA's Press Realease on MyCareTeam [PDF] -

VERICHIP and DIGITAL ANGEL, IMPLANTABLE RFID GLUCOSE-SENSING MICROCHIP

September 24, 2007 - VeriChip Corporation (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, and Digital Angel Corporation (AMEX: DOC), owner of Patent No. 7,125,382 for an embedded bio-sensor system, announced they have entered into a memorandum of understanding with RECEPTORS LLC, an expert in the field of proteomics and the development of artificial receptors to develop a prototype renewable glucose sensor to use in conjunction with an implantable bio-sensing RFID microchip to measure glucose levels in the human body. VeriChip will manage the partnership project, with the assistance of Digital Angel, aimed at accelerating the development of an embedded glucose bio-sensing system for humans. RECEPTORS will be responsible for demonstrating a self-contained glucose-sensing system in Phase I of the project...
VeriChip's Press Release - Digital Angel's press Release - RECEPTORS' Press release [PDF] -

HMM , Blood Glucose Meter for Self-Monitoring With Bluetooth Technology

the First CE-Certified and EU-Registered Blood Glucose Meter for Self-Monitoring With Bluetooth Technology on the Market :

October 4, 2007 - HMM Heidelberger-Medical-Marketing GmbH - Always One Step Ahead.
"Finally - our smartLABgenie is available on the market. Initiator of this product introduction was the desire of many patients for a compact, easy-to-use and at the same time modern tool to smoothly and easily control every day influences on diabetics. The huge advantage: The Bluetooth option renders it possible to integrate our smartLABgenie in every telemedicine system, as well as to transfer data via cell phone and PC..."... HMM's Press Release -

Home Diagnostics on Microsoft HealthVault

Thursday October 4, 2007 - Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced its TRUEtrack® and TRUEread™ blood glucose meters will operate on Microsoft HealthVault, a newly launched consumer health platform. The integrated system will enable TRUEtrack and TRUEread users to download data directly from the meter to the online platform, providing the ability to collect, organize and share diabetes management information in a privacy- and security-enhanced setting... Home Diagnostics' Press Release -

Phylonix Phase II SBIR to Develop Zebrafish Models for Eye Diseases

October 2, 2007- Phylonix Pharmaceuticals, Inc. announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for "New Models for Eye Diseases" will support the Phylonix program over a period of three years... Phylonix is modeling a number of eye diseases in zebrafish including diabetic retinopathy and AMD, the two leading causes of blindness in adults in the industrialized world... Phylonix Pharmaceuticals' Press Release -

CardioVascular BioTherapeutics, Phase I Wound Healing Trial

Oct. 2, 2007--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) today announced the completion of its Phase I wound healing clinical trial aimed at evaluating the safety and tolerability of the company's protein-based drug candidate (CVBT-141B), formulated with human fibroblast growth factor -1 (FGF-1), in patients suffering from either diabetic or venous stasis ulcers. FGF-1 was applied topically in 8 subjects at a single site and was found to be well tolerated... CardioVascular BioTherapeutics' Press Release -

Generex Biotechnology, new United States Patent

Mass., Oct. 2, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that the United States Patent and Trademark Office has granted the Company a new United States Patent.
The patent, titled ``Metered Dose Spray Device for Use with Macromolecular Pharmaceutical Agents such as Insulin,''... Generex Biotechnology's Press Release -

DiaMedica, phase II results for DM-71 in type 2 diabetes trial

October 1, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce exciting results for DM-71 in its proof-of-concept phase II clinical study in type 2 diabetes... DiaMedica's Press Release -

Novartis, Galvus European approval as new treatment for type 2 diabetes

September 28, 2007 - Galvus (vildagliptin), a new once-daily oral treatment for patients with type 2 diabetes, has been granted European Union approval. Galvus is the only drug in its class to offer such a broad range of indications for use in combination therapies with other anti-diabetic medicines... Novartis' Press Release -